calendar
29,013 catalysts · 9,524 approval · 5,000 device 510k · 4,728 grant · 2,630 8k filing · 2,000 device pma · 2,000 device recall
next 91 dayslessmore
MonWedFri
29,013 catalysts · 9,524 approval · 5,000 device 510k · 4,728 grant · 2,630 8k filing · 2,000 device pma · 2,000 device recall
Sponsor: NOVO. Form: SOLUTION. Route: SUBCUTANEOUS
Sponsor: BAXTER HLTHCARE. Form: INJECTABLE. Route: INJECTION
Sponsor: BAXTER HLTHCARE. Form: INJECTABLE. Route: INJECTION
Sponsor: ACTAVIS. Form: INJECTABLE. Route: INJECTION
Sponsor: ELI LILLY AND CO. Form: INJECTABLE. Route: INJECTION
Sponsor: NOVEL LABS INC. Form: TABLET. Route: ORAL
Sponsor: GLAND. Form: INJECTABLE. Route: INJECTION
Sponsor: SUPERNUS PHARMS. Form: CAPSULE, EXTENDED RELEASE. Route: ORAL
Sponsor: SANOFI AVENTIS US. Form: INJECTABLE. Route: INJECTION
Sponsor: VIIV HLTHCARE. Form: TABLET. Route: ORAL
Sponsor: NOVO. Form: SOLUTION. Route: SUBCUTANEOUS
Sponsor: SPECGX LLC. Form: TABLET. Route: SUBLINGUAL
Sponsor: BOEHRINGER INGELHEIM. Form: TABLET, EXTENDED RELEASE. Route: ORAL
Sponsor: BOEHRINGER INGELHEIM. Form: TABLET. Route: ORAL
Sponsor: BOEHRINGER INGELHEIM. Form: TABLET. Route: ORAL
Sponsor: BOEHRINGER INGELHEIM. Form: TABLET. Route: ORAL
Sponsor: PFIZER INC. Form: INJECTABLE. Route: INJECTION
Sponsor: PFIZER. Form: TABLET, EXTENDED RELEASE. Route: ORAL
Sponsor: PF PRISM CV. Form: TABLET. Route: ORAL
Sponsor: ABBVIE INC. Form: VIAL
Sponsor: GLAXOSMITHKLINE. Form: INJECTABLE. Route: SUBCUTANEOUS
Sponsor: GLAXOSMITHKLINE. Form: SPRAY. Route: NASAL
Sponsor: GLAXOSMITHKLINE. Form: TABLET. Route: ORAL
Sponsor: NOVEL LABS INC. Form: TABLET. Route: ORAL
Sponsor: PF PRISM CV. Form: TABLET. Route: ORAL
Sponsor: SANOFI AVENTIS US. Form: TABLET. Route: ORAL
Sponsor: EXELIXIS INC. Form: TABLET. Route: ORAL
Sponsor: BRISTOL MYERS SQUIBB. Form: INJECTABLE. Route: INJECTION
Sponsor: ABBVIE. Form: TABLET. Route: ORAL
Sponsor: PHARMACYCLICS LLC. Form: CAPSULE. Route: ORAL
Sponsor: TAKEDA PHARMS USA. Form: TABLET. Route: ORAL
Sponsor: TAKEDA PHARMS USA. Form: TABLET. Route: ORAL
Sponsor: INGENUS PHARMS LLC. Form: TABLET. Route: ORAL
Sponsor: GLENMARK PHARMS LTD. Form: TABLET. Route: ORAL
Sponsor: SCIEGEN PHARMS. Form: TABLET. Route: ORAL
Sponsor: ALEMBIC. Form: TABLET, FOR SUSPENSION. Route: ORAL
Sponsor: ALEMBIC. Form: TABLET, FOR SUSPENSION. Route: ORAL
Sponsor: ALEMBIC. Form: TABLET, FOR SUSPENSION. Route: ORAL
Sponsor: MERCK SHARP DOHME. Form: SOLUTION. Route: INTRAVENOUS
Sponsor: SCHERING. Form: SUSPENSION. Route: ORAL
Sponsor: MERCK SHARP DOHME. Form: TABLET, DELAYED RELEASE. Route: ORAL
Sponsor: SANOFI AVENTIS US. Form: TABLET. Route: ORAL
Sponsor: SANOFI AVENTIS US. Form: CAPSULE. Route: ORAL
Sponsor: BRISTOL MYERS SQUIBB. Form: INJECTABLE. Route: INJECTION
Sponsor: BRISTOL MYERS SQUIBB. Form: INJECTABLE. Route: INJECTION
Sponsor: BRISTOL MYERS SQUIBB. Form: INJECTABLE. Route: INJECTION
Sponsor: BRISTOL MYERS SQUIBB. Form: INJECTABLE. Route: INJECTION
Sponsor: BRISTOL MYERS SQUIBB. Form: INJECTABLE. Route: INJECTION
Sponsor: REGENERON PHARMACEUTICALS. Form: INJECTABLE. Route: INJECTION
Sponsor: EXELIXIS. Form: CAPSULE. Route: ORAL